GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Add Yahoo as a preferred source to see more of our stories on Google. A GSK logo is seen on the side of an office building in Poznan, Poland. (Getty Images) This story was originally published on ...

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A Phase 2, Multicenter, Open Label, Non-randomized Study to ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ambitions with a glimmer of hope. Following last week’s negative feedback ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. market, GSK has suffered a serious setback at the hands of the FDA’s Oncologic Drugs Advisory Committee (ODAC) ...

GSK finally has the long-awaited FDA approval it sought for blood cancer drug Blenrep. Three years after the pharmaceutical giant pulled the multiple myeloma therapy from the market, the FDA approved ...

(RTTNews) - GSK plc (GSK, GSK.L) issued an update on FDA advisory committee review of Blenrep combinations for patients with relapsed/refractory multiple myeloma. GSK said it remains confident in the ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. The Food and Drug Administration on Thursday delivered a split decision ...

Comeback stories are often the stuff of movies, but GSK is showing they can also happen in pharmaceuticals. The multiple myeloma medicine Blenrep has returned to the market three years after GSK ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

July 24 (Reuters) - The European Union has approved GSK's (GSK.L), opens new tab drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British ...